摘要
Homologous recombination repair deficiency (HRD) results in a defect in DNA repair and is a frequent driver of tumorigenesis. Poly(ADP-ribose) polymerase inhibitors (PARPi) or platinum-based therapies have increased theraputic effectiveness when treating HRD positive cancers. For breast cancer and ovairan can-cer HRD companion diagnostic tests are commonly used. However, the currently used HRD tests are based on high-depth genome sequencing or hybridization-based capture sequencing, which are technically com-plex and costly. In this study, we modified an existing method named shallowHRD, which uses low-pass whole genome sequencing (WGS) for HRD detection, and estimated the performance of the modified shal-lowHRD pipeline. Our shallowHRD pipeline achieved an AUC of 0.997 in simulated low-pass WGS data, with a sensitivity of 0.981 and a specificity of 0.964; and achieved a higher HRD risk score in clinical BRCA-deficient breast cancer samples ( p = 5.5 x 10 -5, compared with BRCA-intact breast cancer sam-ples). We also estimated the limit of detection the shallowHRD pipeline could accurately predict HRD status with a minimum sequencing depth of 0.1 x, a tumor purity of > 20%, and an input DNA amount of 1 ng. Our study demostrates using low-pass sequencing, HRD status can be determined with high accuracy using a simple approach with greatly reduced cost.
学科与关键词
- ShallowHRD status acts as an effective prognostic predictor in ovarian cancer patients treated by poly (ADP-ribose) polymerase inhibitors (PARPis)Guo, Yuanli; He, Xinxin; Tan, Yanming; Liu, Junfeng; Chen, Huadong; Huang, Yi; Zhang, Chao; Tao, Ying*; Chen, Shan*Journal of Cancer Research and Clinical Oncology, 2023, 149(17): 15839-15844.
- Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic ResolutionsZhang, Meng; Ma, Si-Cong; Tan, Jia-Le; Wang, Jian; Bai, Xue; Dong, Zhong-Yi*; Zhang, Qing-Xue*Frontiers in Oncology, 2021, 11: 772604.被引 1
- Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approachesGuffanti, Federica; Mengoli, Ilaria; Damia, Giovanna*Frontiers in Oncology, 2024, 14: 1405361.被引 2
